DFO

(redirected from Deferoxamine)
Also found in: Medical, Wikipedia.
AcronymDefinition
DFODepartment of Fisheries and Oceans (Canada)
DFODesignated Federal Official
DFODisaster Field Office (US FEMA)
DFOData Flow Object
DFODerived Format Object
DFOData Flow Operator
DFODispatcher Failover
DFODarkfall Online (online gaming)
DFODeferoxamine
DFODivisional Forest Officer
DFODairy Farmers of Ontario (Canada)
DFODirector of Financial Operations (various organizations)
DFODirector of Flight Operations (airline rank)
DFODistillate Fuel Oil
DFODirect Factory Outlet (Australian retail center)
DFODistrict Forest Office
DFODartmouth Flood Observatory
DFODrilling Fluid Operator (offshore oil & gas)
DFO1,8-Diazafluoren-9-One (forensic chemical)
DFODirector of Field Operations
DFODolphins Fanatics Online (football website)
DFODone Fell Out
DFODislodged Foreign Object (gaming; World of Warcraft)
DFODeutscher Falkenorden (German Falcon Order)
DFODes Filles en Ovalie (French: Girls in Rugby)
DFODiesel Fuel Oil
DFODigital Fuel Optimizer (RevTech motorcycle fuel control system)
DFODell Factory Outlet
DFODonor Funded Operation (World Bank)
DFODate File Opened (US DHS)
DFODone Fell Over
DFODining Facility Operation
DFODistance from Origin
DFODungeon Fighter Online (video game)
DFODivisional Finance Officer
DFODocumentation for Operations
DFODuty Field Officer (UK)
DFODumb Freakin' Operator (polite form)
DFODiploma in Front Office (various educational institutions)
References in periodicals archive ?
Status of thyroid function and iron overload in adolescents and young adults with beta thalassemia major treated with deferoxamine in Jordan.
Xi, "Hemoglobin and iron handling in brain after subarachnoid hemorrhage and the effect of deferoxamine on early brain injury," Journal of Cerebral Blood Flow and Metabolism, vol.
Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
Ferrostatin-1 and deferoxamine are iron-depleting agents that inhibit ferroptosis (Louandre et al.
Initial chelation therapy with deferoxamine was associated with poor compliance due to slow parenteral infusions and poor long-term outcome therefore oral chelating drugs deferasirox and deferiprone were introduced to prevent complications of iron over load, which showed improved compliance and efficacy.
Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.
Deferoxamine Deferasirox Deferiprone diethylenetriamminepenta-acetic acid Deferasirox (ICL670A) and Pyridoxalisonicotinoylhydrazone (PIH) are potent chelating drugs actively used in thalassemic patients (Hoffbrand 1995; Pignatti and Galanello 2009; Waldmeier et al.
The iron chelators available are deferoxamine (given parenterally), deferiprone and deferasirox (given orally).
Deferoxamine chelation can be administered to patients who refuse or cannot withstand phlebotomy (i.
10) Deferoxamine given intravenously (IV) or subcutaneously has been the standard chelation agent.
Deferoxamine protects against elimination processes [41].